



## Transgene Announces Financial Calendar for 2015

---

**Strasbourg, France, January 8, 2015** - Transgene SA (Euronext: TNG) today announced its financial reporting dates for 2015:

<b>March 24:</b>	2014 Fiscal Year Results
<b>April 22:</b>	First Quarter 2015 Financial Results
<b>June 11:</b>	Annual Shareholders' Meeting
<b>September 10:</b>	First Half 2015 Financial Results
<b>October 21:</b>	Third Quarter 2015 Financial Results

### About Transgene:

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at [www.transgene.fr](http://www.transgene.fr).

### **Contacts:**

#### **Transgene:**

Elisabetta Castelli, Director Investor Relations  
+33 (0)3 88 27 91 21

Laurie Doyle, Director Investor Relations US &  
Corporate Communications  
+1 (339) 832 0752

[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

#### **For media: MC Services**

Raimund Gabriel  
+49 89 210 228 30  
[raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

Shaun Brown  
+44 207 148 5998  
[shaun.brown@mc-services.eu](mailto:shaun.brown@mc-services.eu)